2021.09.29 · Company News

Huangpu District Party Committee Secretary Chen Yong visits Reforgene

Huangpu District Party Committee Secretary Chen Yong visits Reforgene

On September 27, Chen Yong, Secretary of the CPC Huangpu District Committee of Guangzhou, led a delegation to Guangzhou Reforgene Medicine Co., Ltd. to conduct research and guidance on the development of representative innovative pharmaceutical enterprises, industry trends, and talent and policy support. The visiting leaders also included Sun Xuewei, Inspector of the Development District Management Committee, Dong Yanjun, Director of the District Government Office, Chen Weiquan, Director of the District Science and Technology Bureau, and Wu Yun, Deputy Director.

At the discussion, Dr. Liang Junbin reported on the company's development on behalf of Reforgene. Reforgene is a leading high-tech pharmaceutical enterprise in China, in a stage of rapid development, dedicated to the development of curative medicines centered on gene editing. Gene editing technology is an emerging drug application direction of recent years and a future form of medicine. The two sides also discussed the industrial application value and characteristics of this technology in medical, health and other life science fields. Regarding enterprise development, Secretary Chen Yong also learned about the R&D progress of the company's pipeline products, and expressed the hope that the products would enter clinical development as soon as possible to generate social benefits and become accessible medicines for patients.

Subsequently, Secretary Chen Yong and his delegation visited Reforgene's R&D and office environment, and learned about and provided guidance on important aspects of the company's development, such as business operations and talent recruitment. Secretary Chen Yong encouraged Reforgene to continue to do well in technological innovation and become an outstanding leading enterprise in the industry.

← Back to news
Reforgene Medicine

About Reforgene

Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.

Learn more →

Media Contact

info@reforgene.com · BD@reforgene.com